NASDAQ:IRIX IRIDEX - IRIX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding IRIDEX Co. Please log in to your account or sign up in order to add this asset to your watchlist. $2.08 -0.01 (-0.48%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.05▼$2.1450-Day Range$2.01▼$2.4652-Week Range$1.96▼$5.39Volume7,557 shsAverage Volume14,957 shsMarket Capitalization$33.30 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media IRIDEX MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside44.2% Upside$3.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.53Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.45) to ($0.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.60 out of 5 starsComputer And Technology Sector552nd out of 604 stocksElectromedical Equipment Industry19th out of 24 stocks 3.0 Analyst's Opinion Consensus RatingIRIDEX has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, IRIDEX has a forecasted upside of 44.2% from its current price of $2.08.Amount of Analyst CoverageIRIDEX has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IRIX. Previous Next 0.0 Dividend Strength Dividend YieldIRIDEX does not currently pay a dividend.Dividend GrowthIRIDEX does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IRIX. Previous Next 2.5 News and Social Media Coverage News SentimentIRIDEX has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.37 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 2 news articles for IRIDEX this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IRIDEX insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of IRIDEX is held by insiders.Percentage Held by InstitutionsOnly 28.63% of the stock of IRIDEX is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IRIDEX are expected to grow in the coming year, from ($0.45) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IRIDEX is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IRIDEX is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIRIDEX has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IRIDEX (NASDAQ:IRIX) StockIRIDEX Corp. engages in developing, manufacturing, and marketing medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. Its products include lasers, laser delivery and glaucoma devices, retinal surgical instruments, veterinary, and ENT. The company was founded by Eduardo Arias, Theodore A. Boutacoff, David M. Buzawa and James L. Donovan in February 1989 and is headquartered in Mountain View, CA.Read More Receive IRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IRIDEX and its competitors with MarketBeat's FREE daily newsletter. Email Address IRIX Stock News HeadlinesMarch 23, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on IRIDEX (NASDAQ:IRIX)March 15, 2023 | americanbankingnews.comIRIDEX (NASDAQ:IRIX) Now Covered by StockNews.comMarch 24, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 13, 2023 | finance.yahoo.comIRIDEX Corporation (NASDAQ:IRIX) Q4 2022 Earnings Call TranscriptMarch 9, 2023 | finance.yahoo.comIridex Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 7, 2023 | finance.yahoo.comIridex to Present at the 35th Annual Roth ConferenceMarch 2, 2023 | finance.yahoo.comWe're Keeping An Eye On IRIDEX's (NASDAQ:IRIX) Cash Burn RateMarch 2, 2023 | finance.yahoo.comIridex Introduces New Research and Showcases Five Events at the AGS MeetingMarch 24, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.February 23, 2023 | finance.yahoo.comIridex to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023January 10, 2023 | finance.yahoo.comIridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022December 6, 2022 | finance.yahoo.comIridex to Participate in Fireside Chat with Stifel Equity ResearchNovember 13, 2022 | finance.yahoo.comIRIDEX Third Quarter 2022 Earnings: Beats ExpectationsNovember 10, 2022 | finance.yahoo.comIridex Announces Record Third Quarter 2022 Financial ResultsNovember 3, 2022 | finance.yahoo.comA number of insiders bought IRIDEX Corporation (NASDAQ:IRIX) stock last year, which is great news for shareholdersOctober 27, 2022 | finance.yahoo.comIridex to Report Third Quarter 2022 Financial Results on November 10, 2022October 7, 2022 | benzinga.comGlobal Retinal Surgery Devices Market Report 2022-2027 Featuring Alcon, Carl Zeiss, Topcon, Bausch Health - BenzingaOctober 5, 2022 | businesswire.comGlobal Eye Surgical Market Research and Forecast 2022-2028: Increasing Prevalence of Eye-Related Diseases Driving Growth - ResearchAndMarkets.com - Business WireSeptember 30, 2022 | finance.yahoo.comIridex Showcases its Non-Incisional Treatments for Glaucoma, Introduces Sweep Management Software, and Hosts 8 Physician Presentations at AAO 2022 - Yahoo FinanceSeptember 29, 2022 | globenewswire.comIridex Showcases its Non-Incisional Treatments for Glaucoma, Introduces Sweep Management Software, and Hosts 8 Physician Presentations at AAO 2022 - GlobeNewswireSeptember 28, 2022 | businesswire.comGlobal Retinal Surgery Devices Market Analysis Report 2022-2027: Major Company Profiles, Deals, Strategies, Growth Drivers and Recent Developments - ResearchAndMarkets.com - Business WireSeptember 24, 2022 | finance.yahoo.comWe're Hopeful That IRIDEX (NASDAQ:IRIX) Will Use Its Cash Wisely - Yahoo FinanceSeptember 23, 2022 | finance.yahoo.comWe're Hopeful That IRIDEX (NASDAQ:IRIX) Will Use Its Cash WiselySeptember 22, 2022 | businesswire.comRetinal Surgery Devices Market Report 2022: Increasing Demand for Minimally Invasive Surgeries Drives Growth - ResearchAndMarkets.com - Business WireAugust 29, 2022 | morningstar.comNorth American Morning Briefing: Powell's -2- - MorningstarAugust 26, 2022 | benzinga.comBenzinga's Top Ratings Upgrades, Downgrades For August 26, 2022 - BenzingaAugust 26, 2022 | seekingalpha.comIridex stock falls 7% as Stifel sees limited potential volume upside for glaucoma system - Seeking AlphaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IRIDEX and its competitors with MarketBeat's FREE daily newsletter. Email Address IRIX Company Calendar Last Earnings11/11/2021Today3/24/2023Next Earnings (Estimated)5/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorComputer and Technology Current SymbolNASDAQ:IRIX CUSIPN/A CIK1006045 Webwww.iridex.com Phone(650) 940-4700Fax650-940-4710Employees119Year Founded1989Price Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$3.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+43.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,550,000.00 Net Margins-13.25% Pretax Margin-13.13% Return on Equity-39.69% Return on Assets-16.69% Debt Debt-to-Equity RatioN/A Current Ratio2.87 Quick Ratio2.02 Sales & Book Value Annual Sales$56.97 million Price / Sales0.59 Cash FlowN/A Price / Cash FlowN/A Book Value$1.08 per share Price / Book1.94Miscellaneous Outstanding Shares16,010,000Free Float15,351,000Market Cap$33.46 million OptionableNot Optionable Beta1.26 Social Links Key ExecutivesDavid I. BrucePresident, Chief Executive Officer & DirectorPatrick MercerChief Operating OfficerFuad AhmadChief Financial OfficerGeorge R. MarcellinoVice President-Clinical AffairsSusan BruceExecutive AdministratorKey CompetitorsUTStarcomNASDAQ:UTSIOptical CableNASDAQ:OCCiCADNASDAQ:ICADClearOneNASDAQ:CLRONortech SystemsNASDAQ:NSYSView All CompetitorsInsiders & InstitutionsRenaissance Technologies LLCSold 22,700 shares on 2/13/2023Ownership: 2.691%Isthmus Partners LLCBought 16,033 shares on 2/10/2023Ownership: 2.088%Nandini DeviBought 2,000 shares on 5/20/2022Total: $6,200.00 ($3.10/share)View All Insider TransactionsView All Institutional Transactions IRIX Stock - Frequently Asked Questions Should I buy or sell IRIDEX stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRIDEX in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" IRIX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IRIX, but not buy additional shares or sell existing shares. View IRIX analyst ratings or view top-rated stocks. What is IRIDEX's stock price forecast for 2023? 1 equities research analysts have issued 1 year target prices for IRIDEX's shares. Their IRIX share price forecasts range from $3.00 to $3.00. On average, they anticipate the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 43.5% from the stock's current price. View analysts price targets for IRIX or view top-rated stocks among Wall Street analysts. How have IRIX shares performed in 2023? IRIDEX's stock was trading at $2.01 at the beginning of the year. Since then, IRIX stock has increased by 4.0% and is now trading at $2.09. View the best growth stocks for 2023 here. When is IRIDEX's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our IRIX earnings forecast. How were IRIDEX's earnings last quarter? IRIDEX Co. (NASDAQ:IRIX) announced its quarterly earnings results on Thursday, November, 11th. The medical equipment provider reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. The medical equipment provider earned $13.26 million during the quarter, compared to analyst estimates of $11.90 million. IRIDEX had a negative net margin of 13.25% and a negative trailing twelve-month return on equity of 39.69%. During the same quarter in the previous year, the business earned ($0.12) earnings per share. What guidance has IRIDEX issued on next quarter's earnings? IRIDEX issued an update on its FY 2023 earnings guidance on Thursday, March, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $57.00 million-$59.00 million, compared to the consensus revenue estimate of $60.08 million. What is Theodore A. Boutacoff's approval rating as IRIDEX's CEO? 7 employees have rated IRIDEX Chief Executive Officer Theodore A. Boutacoff on Glassdoor.com. Theodore A. Boutacoff has an approval rating of 64% among the company's employees. What other stocks do shareholders of IRIDEX own? Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include NVIDIA (NVDA), Trevena (TRVN), CTI BioPharma (CTIC), Agile Therapeutics (AGRX), Ampio Pharmaceuticals (AMPE), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA), Lipocine (LPCN), Rigel Pharmaceuticals (RIGL) and SCYNEXIS (SCYX). What is IRIDEX's stock symbol? IRIDEX trades on the NASDAQ under the ticker symbol "IRIX." Who are IRIDEX's major shareholders? IRIDEX's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.69%), Isthmus Partners LLC (2.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Nandini Devi and Robert Earle Grove. View institutional ownership trends. How do I buy shares of IRIDEX? Shares of IRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IRIDEX's stock price today? One share of IRIX stock can currently be purchased for approximately $2.09. How much money does IRIDEX make? IRIDEX (NASDAQ:IRIX) has a market capitalization of $33.46 million and generates $56.97 million in revenue each year. The medical equipment provider earns $-7,550,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. How many employees does IRIDEX have? The company employs 119 workers across the globe. How can I contact IRIDEX? IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The official website for the company is www.iridex.com. The medical equipment provider can be reached via phone at (650) 940-4700, via email at investors@iridex.com, or via fax at 650-940-4710. This page (NASDAQ:IRIX) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.